Haemonetics Corporation
HAE
Ранг среди акций
#3280
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Цена акции
$118.26
Рыночная капитализация
$5.38B
Изменение (1 день)
-0.20%
Изменение (1 год)
133.21%
Страна
US
Торговля Haemonetics Corporation (HAE)
Категория
Healthcare
Коэффициент P/E для Haemonetics Corporation (HAE)
Коэффициент P/E на October 2026 TTM: 58.79
Согласно последним финансовым отчетам и цене акций Haemonetics Corporation, текущий P/E (TTM) составляет 58.79. В конце 2024 у компании был P/E на уровне 36.57.
История P/E компании Haemonetics Corporation с 2000 по 2026
P/E на конец каждого года
| Год | P/E коэффициент | Изменить |
|---|---|---|
| 2026 (TTM) | 58.79 | 209.92% |
| 2025 | 18.97 | -48.14% |
| 2024 | 36.57 | 0.43% |
| 2023 | 36.41 | -51.54% |
| 2022 | 75.14 | 5.15% |
| 2021 | 71.46 | 6.87% |
| 2020 | 66.87 | -18.39% |
| 2019 | 81.94 | -3.25% |
| 2018 | 84.69 | -206.46% |
| 2017 | -79.55 | 146.27% |
| 2016 | -32.30 | -123.96% |
| 2015 | 134.83 | 185.97% |
| 2014 | 47.15 | -14.48% |
| 2013 | 55.13 | 108.66% |
| 2012 | 26.42 | 26.60% |
| 2011 | 20.87 | -15.24% |
| 2010 | 24.62 | 5.04% |
| 2009 | 23.44 | -19.61% |
| 2008 | 29.16 | 14.54% |
| 2007 | 25.46 | 30.83% |
| 2006 | 19.46 | -27.03% |
| 2005 | 26.67 | 2.01% |
| 2004 | 26.14 | 34.39% |
| 2003 | 19.45 | -29.80% |
| 2002 | 27.71 | -76.06% |
| 2001 | 115.73 | 274.57% |
| 2000 | 30.90 | 0.00% |
P/E для схожих компаний или конкурентов
| Компания | P/E Ratio | Разница P/E | Страна |
|---|---|---|---|
| 33.11 | -43.68% |
US
|
|
| 21.39 | -63.62% |
IE
|
|
| 28.94 | -50.77% |
US
|
|
| 17.34 | -70.51% |
US
|
|
| - | - |
DE
|
Как читать P/E Ratio?
Коэффициент цена/прибыль (P/E Ratio) отражает соотношение между ценой акции компании и её прибылью на акцию.
Низкий, но положительный P/E говорит о том, что компания приносит высокую прибыль при низкой оценке и может быть недооценена. Высокий отрицательный (близкий к 0) P/E указывает на значительные убытки.
Компании с P/E выше 30 или отрицательным считаются "акциями роста" — инвесторы ожидают роста или будущей прибыли.
Компании с положительным P/E ниже 10 считаются "ценностными акциями", т.е. уже прибыльны, но с низким потенциалом роста.